Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that 62% of premenopausal women with female pattern hair loss reported improvement when treated with oral finasteride and an oral contraceptive containing drospirenone and ethinyl estradiol.

This review discusses female pattern hair loss, emphasizing its complex causes and the limited treatment options available, and reports no new clinical results.

This retrospective study found that adipose-derived stem cell-conditioned media increased hair density and thickness in women with female pattern hair loss over 12 weeks, with no severe adverse effects reported.

This review discusses laser/light treatments for pattern hair loss and reports no clinical validation of current devices; experts recommend physician evaluation to exclude other medical conditions.

This study suggests that 5 mg/day oral finasteride may increase hair density and thickness in normoandrogenic Asian women with female pattern hair loss over 12 months.

This study found that male pattern baldness in European males is strongly heritable and associated with genetic markers linked to earlier puberty, bone density, and pancreatic function.

This review discusses the role of Prostaglandin D2 and its synthase in androgenetic alopecia but reports no new clinical findings, suggesting pathways for future therapeutic development.

This case report describes a patient with complete androgen insensitivity syndrome experiencing female pattern hair loss, suggesting that factors beyond direct androgen action may contribute to this condition in women.

This study suggests that the HDAC9 gene is a third susceptibility gene for male-pattern baldness, with significant associations found in both German and Australian samples.

This study suggests that Botox injections may increase hair count and reduce hair loss in men with androgenetic alopecia, potentially through increased blood flow and oxygen to the scalp.

This study found that long-term flutamide treatment reduced hair loss in women with female pattern hair loss, but liver-related dropouts were minimized at a very low dose of 62.5 mg/day.

This study suggests that the AGA risk haplotype in Europeans was driven to high frequency by positive selection, likely associated with a variant in the EDA2R gene.

This study found that mesotherapy with a dutasteride-containing preparation improved hair growth indicators in female pattern hair loss better than saline, with minimal side effects and greater effectiveness in patients with shorter disease duration.

This review assessed available treatments for female pattern hair loss and found that minoxidil improved hair regrowth compared to placebo, though high-quality evidence was limited for other interventions.

This study found that early-onset androgenic alopecia is associated with a higher risk of developing prostate cancer, although it was not linked to earlier diagnosis or more aggressive tumors.

This study found that a genetic model using SNPs can predict early-onset male-pattern baldness with moderate accuracy, which may assist in decisions about interventions.

This study found that sebum excretion is not increased in women with female pattern hair loss, suggesting nonandrogenic factors may contribute to hair loss in some women without hirsutism.

In this study, topical 2% minoxidil did not significantly improve hair density measures in men with male pattern baldness, although there was no deterioration, suggesting a potential prophylactic effect.

This study found that miniaturization of hair is present in some women with androgenetic alopecia, but diagnosis may also be based on differences in hair shaft diameter between scalp regions.

This study observed that specific trichoscopic features like white peripilar signs, scalp pigmentation, and focal atrichia are associated with advanced female pattern hair loss in Fitzpatrick skin type III patients.

This study observed that frontal plus moderate vertex baldness at age 45 was associated with a higher risk of aggressive prostate cancer in a large cohort.

This study found that topical application of niacin derivatives significantly increased hair fullness in women with female pattern hair loss compared to a placebo after six months.

This review discusses the physiology and potential hormonal mechanisms involved in female pattern hair loss, as well as the current hormonal and hormone-modifying treatments available, but reports no new research findings.

In this study, fiber implantation for pattern baldness was deemed ineffective and resulted in complications such as infection, scarring, and permanent hair loss, making it an unacceptable treatment option.

This study suggests that any baldness, particularly moderate balding, is associated with a higher risk of fatal prostate cancer in men, supporting a possible link between hair loss and prostate cancer mechanisms.

This study observed a potential association between the CC genotype of rs4646 and female pattern hair loss, but the authors advise caution due to lack of experiment-wide significance and recommend replication.

This study reviewed clinical trials and found that low-level laser therapy significantly increased hair diameter or density in both men and women with pattern hair loss compared to a sham device, though the involvement of industry relationships in some studies suggests cautious interpretation.

This study found that 2% minoxidil solution significantly increased non-vellus hair counts and regrowth rates compared to placebo in men with early androgenic alopecia, suggesting it is an effective treatment.

In this study, reduced hair density, diameter, and follicle miniaturization were key characteristics of female pattern hair loss in Southern Chinese women, with occipital and temporal sites also affected.

This study concluded that there is no association between male pattern baldness and the severity or presence of coronary artery disease as measured by Gensini and Rentrop scores.